Patients with pancreatic cancer might consider joining a Phase II clinical trial underway at Baylor University Medical Center, part of Baylor Scott & White Health, to evaluate a new chemotherapy protocol. The trial will study the effectiveness of a particular therapy in patients with non-metastatic disease.
“Our primary objective with this trial is to try to control micrometastatic disease,” said Carlos Becerra, MD, a hematologist-oncologist on the medical staff at Baylor University Medical Center and medical director of the Innovative Clinical Trials Center.
“Even when it is not seen on scans, the disease is probably there. By incorporating chemotherapy, we hope to treat systemic disease sooner.”
A second objective of the study is to determine if the therapy will shrink tumors in patients whose locally advanced disease is inoperable.
Approximately 20 percent of patients with localized pancreatic cancer are potential surgical candidates. Even with surgical removal, the majority of patients will eventually develop metastatic disease and die as a result.
“With pancreatic cancer, surgical resection offers the only chance for a cure. But only a small number of such cancers are considered resectable at diagnosis,” said Scott Celinski, MD, a surgeon on the medical staff at Baylor University Medical Center and an investigator for Baylor Scott & White Research Institute.
“We are hopeful that this new chemotherapy regimen will allow more patients to undergo surgery, as well as shrink localized tumors to the point where surgery is more effective.”
The three-year trial will enroll approximately 100 patients.
Learn more about this clinical trial and other research studies at Baylor Scott & White Research Institute, here.